Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder

Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder

Abstract Background Polypharmacy is often prescribed for bipolar disorder, yet medication non-adherence remains a serious problem. This study investigated the regularity in the daily dosage taken of mood stabilizers and second generation antipsychotics. Methods Daily self-reported data on medication...

Full description

Bibliographic Details
Main Authors:	Maximilian Pilhatsch, Tasha Glenn, Natalie Rasgon, Martin Alda, Kemal Sagduyu, Paul Grof, Rodrigo Munoz, Wendy Marsh, Scott Monteith, Emanuel Severus, Rita Bauer, Philipp Ritter, Peter C. Whybrow, Michael Bauer
Format:	Article
Language:	English
Published:	SpringerOpen 2018-05-01
Series:	International Journal of Bipolar Disorders
Subjects:	Bipolar disorder Mood stabilizers Second generation antipsychotics Polypharmacy Adherence
Online Access:	http://link.springer.com/article/10.1186/s40345-018-0118-8

Similar Items

Trajectories of adherence to mood stabilizers in patients with bipolar disorder
by: M. Bauer, et al.
Published: (2019-09-01)

Pattern of Antipsychotic Use and Its Determinants in Razi Psychiatric Hospital
by: Arash Mirabzadeh, et al.
Published: (2012-04-01)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
by: Hiroyuki Kamei
Published: (2022-11-01)

Profiling the Skeletal Muscle Proteome in Patients on Atypical Antipsychotics and Mood Stabilizers
by: Kyle J. Burghardt, et al.
Published: (2022-02-01)

Combination treatment with second generation antipsychotics other than clozapine
by: C. Schmidt-Kraepelin
Published: (2021-04-01)

Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study
by: Ana Aliana Miron, et al.
Published: (2023-01-01)

Antipsychotic prescription and polypharmacy among outpatients with schizophrenia in a Nigerian hospital
by: Ihechiluru Goodnews Anozie, et al.
Published: (2020-01-01)

Prescriptions of Antipsychotics in Younger and Older Geriatric Patients with Polypharmacy, Their Safety, and the Impact of a Pharmaceutical-Medical Dialogue on Antipsychotic Use
by: Eva-Maria Gebauer, et al.
Published: (2022-12-01)

Antipsychotics and risk of natural death in patients with schizophrenia
by: Chen Y, et al.
Published: (2019-07-01)

Antipsychotic polypharmacy: Retrospective evaluation of cases with psychotic disorder followed in outpatient clinic (tur)
by: Şahabettin Çetin, et al.
Published: (2021-05-01)

Application of Antipsychotic Drugs in Mood Disorders
by: Janusz K. Rybakowski
Published: (2023-02-01)

Nationwide study on antipsychotic polypharmacy among forensic psychiatric patients
by: Stine Lassen, et al.
Published: (2023-12-01)

Relative toxicity of mood stabilisers and antipsychotics: case fatality and fatal toxicity associated with self-poisoning
by: Anne E. Ferrey, et al.
Published: (2018-12-01)

Prescription patterns in psychiatric compulsory care: polypharmacy and high-dose antipsychotics
by: Katerina Kaikoushi, et al.
Published: (2021-09-01)

Atypical Antipsychotics and the Human Skeletal Muscle Lipidome
by: Kyle J. Burghardt, et al.
Published: (2018-10-01)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
by: Sang Won Jeon, et al.
Published: (2017-10-01)

Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
by: Norio Yasui‐Furukori, et al.
Published: (2020-09-01)

Effect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: a network meta-analysis of randomised-controlled trialsResearch in context
by: Lingzhuo Kong, et al.
Published: (2024-05-01)

Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics
by: Hikaru Hori, et al.
Published: (2022-05-01)

Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country
by: Kerryn S. Armstrong, et al.

Antipsychotic use in patients with schizophrenia treated in private psychiatry
by: C Valterio
Published: (2005-02-01)

Antipsychotic Polypharmacy among Children and Young Adults in Office-Based or Hospital Outpatient Department Settings
by: Minji Sohn, et al.
Published: (2017-11-01)

Stabilization Beyond Mood: Stabilizing Patients With Bipolar Disorder in the Various Phases of Life
by: Alessio Simonetti, et al.
Published: (2020-04-01)

Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review
by: Amber N. Edinoff, et al.
Published: (2022-03-01)

The Prevalence and Factors Associated With Antipsychotic Polypharmacy in a Forensic Psychiatric Sample
by: Christian Farrell, et al.
Published: (2020-04-01)

The Utah psychotropic oversight program: collaboratively addressing antipsychotic use within youth in foster care without prior authorization
by: Eric T. Monson, et al.
Published: (2023-11-01)

Impact on hospital-wide antipsychotic prescribing practices through physician peer comparison letters
by: Erica A. K. Davis, PharmD, BCPS, BCPP
Published: (2022-01-01)

Antipsychotic prescribing patterns in children and adolescents attending Australian general practice in 2011 and 2017
by: Julie Klau, et al.
Published: (2024-03-01)

Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment
by: Jari Tiihonen, et al.
Published: (2012-01-01)

Characterising the evolution of antipsychotic polypharmacy and clozapine prescribing patterns in schizophrenia patients during psychiatric hospitalisations
by: J. Lagreula, et al.
Published: (2022-06-01)

Psychotropic drug prescription patterns and their predictors among older adult patients with schizophrenia in a tertiary-referral psychiatric hospital
by: Mu- Chun Lin, et al.
Published: (2021-01-01)

Antipsychotic Polypharmacy and High-Dose Antipsychotic Regimens in the Residential Italian Forensic Psychiatric Population (REMS)
by: Gabriele Mandarelli, et al.
Published: (2022-02-01)

Factors associated with high‐dose antipsychotic prescriptions in outpatients with schizophrenia: An analysis of claims data from a Japanese prefecture
by: Tatsuichiro Takahashi, et al.
Published: (2020-09-01)

Antipsychotic Polypharmacy and High Doses in a Rural Portuguese Community Mental Health Service
by: Sara Ramos, et al.
Published: (2021-09-01)

Dosage of antipsychotics in China routine practice
by: T. Zhang, et al.
Published: (2021-04-01)

Effects of Lithium Combined with Second-Generation Antipsychotics for the Treatment of Manic Episodes in Patients with Bipolar Disorder: A Naturalistic Study in China
by: Liu Y, et al.
Published: (2020-11-01)

Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review
by: Doane MJ, et al.
Published: (2021-02-01)

Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project
by: Naoki Hashimoto, et al.
Published: (2023-06-01)

Assessing the synergy between cholinomimetics and memantine as augmentation therapy in Cognitive Impairment in Schizophrenia. A virtual human patient trial using Quantitative Systems Pharmacology
by: Hugo eGeerts, et al.
Published: (2015-09-01)

Predictors for Antipsychotic Dosage Change in the First Year of Treatment in Schizophrenia Spectrum and Bipolar Disorders
by: Petter Andreas Ringen, et al.
Published: (2019-09-01)